Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $413.48 | 12 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $108.40 | 1 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $99.11 | 7 | $0 (2020) |
| Alkermes, Inc. | $97.89 | 1 | $0 (2017) |
| Neurocrine Biosciences, Inc. | $74.48 | 1 | $0 (2018) |
| AbbVie Inc. | $33.60 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $33.60 | 2 | AbbVie Inc. ($33.60) |
| 2020 | $61.13 | 4 | Janssen Pharmaceuticals, Inc ($61.13) |
| 2018 | $195.84 | 3 | Teva Pharmaceuticals USA, Inc. ($108.40) |
| 2017 | $122.91 | 3 | Alkermes, Inc. ($97.89) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/22/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: NEUROSCIENCE | ||||||
| 05/04/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2020 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), SPRAVATO | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Neuroscience | ||||||
| 11/11/2020 | Janssen Pharmaceuticals, Inc | INVEGA TRINZA (Drug), INVEGA SUSTENNA | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: Neuroscience | ||||||
| 03/04/2020 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $12.71 | General |
| Category: Neuroscience | ||||||
| 01/08/2020 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: Neuroscience | ||||||
| 10/31/2018 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $12.96 | General |
| Category: Neuroscience | ||||||
| 03/15/2018 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $74.48 | General |
| Category: NEUROLOGY | ||||||
| 02/02/2018 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $108.40 | General |
| Category: Central Nervous System | ||||||
| 11/02/2017 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $14.23 | General |
| Category: Neuroscience | ||||||
| 10/20/2017 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $10.79 | General |
| Category: Neuroscience | ||||||
| 09/21/2017 | Alkermes, Inc. | Aristada 441 mg (Drug), Aristada 662mg, Aristada 882mg | Food and Beverage | In-kind items and services | $97.89 | General |
| Category: CNS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 212 | 642 | $110,761 | $41,920 |
| 2022 | 5 | 228 | 744 | $128,707 | $44,366 |
| 2021 | 4 | 266 | 674 | $123,502 | $44,895 |
| 2020 | 5 | 389 | 1,284 | $228,008 | $76,136 |
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 79 | 476 | $71,400 | $29,028 | 40.7% |
| 90791 | Psychiatric diagnostic evaluation | Facility | 2023 | 50 | 59 | $20,650 | $6,458 | 31.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 60 | 72 | $12,600 | $4,524 | 35.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 14 | $3,486 | $1,089 | 31.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 21 | $2,625 | $821.94 | 31.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 79 | 542 | $81,300 | $28,905 | 35.6% |
| 90791 | Psychiatric diagnostic evaluation | Facility | 2022 | 52 | 59 | $20,650 | $6,981 | 33.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 47 | $11,407 | $3,990 | 35.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 60 | 67 | $11,725 | $3,615 | 30.8% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 16 | 29 | $3,625 | $874.78 | 24.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 91 | 461 | $69,150 | $26,046 | 37.7% |
| 90791 | Psychiatric diagnostic evaluation | Facility | 2021 | 75 | 81 | $28,348 | $9,751 | 34.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 77 | 88 | $15,400 | $5,043 | 32.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 23 | 44 | $10,604 | $4,055 | 38.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 126 | 873 | $130,950 | $48,681 | 37.2% |
| 90791 | Psychiatric diagnostic evaluation | Facility | 2020 | 109 | 139 | $48,650 | $12,668 | 26.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 112 | 142 | $24,850 | $7,948 | 32.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 24 | 63 | $15,183 | $4,717 | 31.1% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 18 | 67 | $8,375 | $2,122 | 25.3% |
About Dr. Martin Repetto, MD
Dr. Martin Repetto, MD is a Psychiatry healthcare provider based in Mahomet, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881634228.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Martin Repetto, MD has received a total of $413.48 in payments from pharmaceutical and medical device companies, with $33.60 received in 2021. These payments were reported across 12 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($413.48).
As a Medicare-enrolled provider, Repetto has provided services to 1,095 Medicare beneficiaries, totaling 3,344 services with total Medicare billing of $207,317. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry
- Location Mahomet, IL
- Active Since 06/07/2006
- Last Updated 08/05/2024
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1881634228
Products in Payments
- AUSTEDO (Drug) $108.40
- Aristada 441 mg (Drug) $97.89
- INVEGA SUSTENNA (Drug) $77.12
- INGREZZA (Drug) $74.48
- VRAYLAR (Drug) $33.60
- INVEGA TRINZA (Drug) $21.99
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.